Needham Downgrades Kalvista Pharmaceuticals Inc (KALV) to Hold Apr 30, 2026 01:03PM
KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference Apr 8, 2026 07:00AM
Kalvista Pharmaceuticals Inc (KALV) PT Raised to $35 at Needham Jan 9, 2026 07:04AM
Needham says this stock is 2026 winner as oral HAE drug gains early traction Jan 7, 2026 06:30PM
Kalvista Pharmaceuticals Inc (KALV) PT Raised to $32 at Needham Jan 6, 2026 07:08AM


Mar 31, 2025 07:00AM KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference
Nov 5, 2024 07:13AM Kalvista Pharmaceuticals Inc (KALV) PT Lowered to $28 at Needham
Sep 10, 2024 06:30AM KalVista (KALV) Appoints Brian Piekos as CFO
Sep 10, 2024 06:30AM KalVista Appoints Brian Piekos as Chief Financial Officer
Apr 3, 2024 06:30AM KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
Feb 15, 2024 06:31AM KalVista Pharmaceuticals (KALV) Prices $160.1M Offering at $15.25/sh
Feb 15, 2024 06:30AM KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants
Apr 12, 2023 06:30AM KalVista Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference
Apr 11, 2022 07:00AM KalVista Pharmaceuticals to Present at 21st Annual Needham Virtual Healthcare Conference
Mar 10, 2022 10:53AM Kalvista Pharmaceuticals Inc (KALV) PT Lowered to $42 at Needham & Company, Analyst Maintains Buy Rating on Optimistic Tone on Company's Programs
Mar 7, 2022 10:59AM Needham & Company Reiterates Buy Rating on Kalvista Pharmaceuticals Inc (KALV)
Dec 9, 2021 03:35PM Kalvista Pharmaceuticals Inc (KALV) PT Lowered to $48 at Needham & Company
Sep 9, 2021 03:30PM Kalvista Pharmaceuticals Inc (KALV) PT Lowered to $50 at Needham & Company, Following Earnings
Feb 16, 2021 04:01PM KalVista Pharmaceuticals Announces the Closing of its Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Feb 16, 2021 01:49PM Kalvista Pharmaceuticals Inc (KALV) PT Raised to $60 at Needham & Company
Feb 11, 2021 05:57AM KalVista Pharmaceuticals (KALV) Prices 5.375M Share Upsized Common Offering at $36/Sh
Feb 10, 2021 09:52PM KalVista Pharmaceuticals Announces Pricing of an Upsized $193.5 Million Public Offering of Common Stock
Jan 26, 2021 07:26AM UPDATE: Kalvista Pharmaceuticals Inc (KALV) PT Raised to $32 at Needham & Company
Oct 20, 2020 06:28AM Companies with NDRs 10/20
Oct 19, 2020 07:34AM Companies with NDRs 10/19
Apr 9, 2020 07:00AM KalVista Pharmaceuticals to Present at 19th Annual Needham Healthcare Conference
Dec 10, 2019 07:19AM Kalvista Pharmaceuticals Inc (KALV) PT Lowered to $28 at Needham & Company
Oct 24, 2019 06:48AM Companies with NDRs 10/24
Apr 3, 2019 07:30AM KalVista Pharmaceuticals to Present at Needham Healthcare Conference
Mar 20, 2019 06:55AM Needham & Company Starts Kalvista Pharmaceuticals Inc (KALV) at Buy